Data Review on COVID-19 Vaccines for Kids to Get Underway
The United States Food and Drug Administration (FDA) will review 2 months of safety data from clinical trials on the safety and efficacy of COVID-19 vaccines among children ages 5 to 11. This suggests that COVID-19 vaccine manufacturers will seek Emergency Use Authorization (EUA) from the FDA for this age group. The vaccines received EUAs for individuals age 16 and older after the review of 2 months of clinical trial data. Pfizer, which makes the only COVID-19 vaccine to receive full FDA approval thus far, achieved this authorization after providing 6 months of clinical trial data. Pfizer expects to have the 2 months of study results to the FDA by the end of September. The FDA will fast track its review of the data so it is completed with weeks, instead of months. Click here to read more.